Novel RNAi Candidate Advances Toward Clinical Development for Overweight and Obesity
Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively, “Ribo”) announced the successful submission of a Phase 1 Clinical Trial Application (CTA) in the European Union for RBD3133, a novel small interfering RNA (siRNA) therapeutic targeting INHBE (inhibin subunit beta E).
RBD3133 is being developed for potential future use in overweight and obesity, with the aim of addressing underlying metabolic dysfunction.
Key Highlights
-
EU Phase 1 CTA successfully submitted for RBD3133.
-
RBD3133 is a novel siRNA therapeutic targeting INHBE.
-
The candidate is being developed for potential treatment of overweight and obesity.
-
The Phase 1 study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).
-
The study will be the first clinical evaluation of RBD3133 in humans.
-
RBD3133 is designed to selectively silence INHBE, which encodes the protein activin E.
-
The program is supported by human genetic evidence linking INHBE loss-of-function variants with favorable metabolic characteristics.
Why Target INHBE?
Obesity has become a major global public health challenge, affecting more than one billion people worldwide and contributing to conditions including:
-
Type 2 diabetes
-
Cardiovascular disease
-
Other obesity-related metabolic complications
Despite advances in obesity treatment, there remains a need for therapies that can address the underlying biology of metabolic dysfunction and potentially provide durable clinical benefits.
RBD3133 is designed to selectively silence INHBE, a gene encoding activin E.
Human genetic studies have indicated that individuals carrying naturally occurring loss-of-function variants in INHBE may have:
-
Healthier fat distribution
-
Improved metabolic characteristics
-
Lower estimated risk of coronary heart disease
-
Lower estimated risk of type 2 diabetes
These findings provide genetic support for INHBE as a potential therapeutic target for obesity and related metabolic diseases.
Phase 1 Clinical Study
The Phase 1 trial is designed as a randomized, placebo-controlled study in participants with overweight or obesity.
RBD3133 will be administered subcutaneously.
Study Objectives
The trial will evaluate:
-
Safety
-
Tolerability
-
Pharmacokinetics (PK)
-
Pharmacodynamics (PD)
As the first study of RBD3133 in humans, the trial is intended to establish an initial clinical profile and provide a foundation for further development.
Strategic Importance for Ribo
RBD3133 represents an important addition to Ribo’s siRNA development portfolio in cardiovascular and metabolic diseases.
As the company’s first drug candidate targeting obesity, RBD3133 reflects Ribo’s strategic focus on developing innovative therapies for large patient populations with significant unmet medical needs.
“This CTA submission represents another clear step forward for our cardiometabolic pipeline and highlights our ability to translate compelling human genetic evidence into innovative RNAi medicines.”
— Dr. Anders Gabrielsen, Chief Medical Officer, Ribo
About RBD3133
RBD3133 is an investigational siRNA therapeutic designed to selectively silence INHBE.
The program is intended to explore the potential of RNA interference technology to modulate a genetically validated target associated with metabolic health, obesity, and cardiovascular risk.
RBD3133 is currently an investigational candidate and its safety and efficacy have not yet been established in humans.
About Suzhou Ribo Life Science and Ribocure Pharmaceuticals
Suzhou Ribo Life Science Co., Ltd.
Suzhou Ribo Life Science Co., Ltd. (06938.HK) is a global biopharmaceutical company focused on the development and commercialization of small interfering RNA (siRNA)-based therapeutics.
Through its vertically integrated technology platforms, Ribo has developed a differentiated pipeline targeting major disease areas, including:
-
Cardiovascular and metabolic disorders
-
Liver diseases
-
Kidney diseases
-
Other areas of significant unmet medical need
Learn more: www.ribolia.com
Ribocure Pharmaceuticals AB
Ribocure Pharmaceuticals AB, an overseas subsidiary of Suzhou Ribo Life Science, focuses on the global development of oligonucleotide therapies.
Its activities include:
-
Global development of pipeline assets
-
Identification of new therapeutic targets
-
Development of innovative clinical capabilities
-
Conducting clinical trials
-
Advancing siRNA medicines for unmet medical needs worldwide
Learn more: www.ribocure.com
